Human immunodeficiency virus (HIV)-negative plasmablastic lymphoma: A single institutional experience and literature review

Liu, Jane Jijun; Zhang, Ling; Ayala, Ernesto; Field, Teresa; Ochoa-Bayona, José L.; Perez, Lia; Bello, Celeste M.; Chervenick, Paul A.; Bruno, Salvador; Cultrera, Jennifer L.; Baz, Rachid; Kharfan‐Dabaja, Mohamed A.; Raychaudhuri, Jyotishankar; Sotomayor, Eduardo M.; Sokol, Lubomir

doi:10.1016/j.leukres.2011.06.023

Cited by 105 publications

(98 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Four patients had CD20-negative plasmablastic lymphoma, a malignancy that is commonly seen in T-cell immunosuppressed individuals infected with HIV, 8 and that has been marginally described in recipients of stem cell transplants. 19,20 In this regard, the early period after UCBT is characterized by deep immune suppression with low levels of CD4 þ T cells that could favor the development of this complication. 19 One strength of the present study is the fact that clonality was evaluated in all cases.…”

Section: Discussionmentioning

confidence: 99%

“…19,20 In this regard, the early period after UCBT is characterized by deep immune suppression with low levels of CD4 þ T cells that could favor the development of this complication. 19 One strength of the present study is the fact that clonality was evaluated in all cases. As expected, we found evidence of monoclonality in cases of monomorphic EBV-PTLD, whereas in the only patient with polymorphic disease two different IGH clonal rearrangements were seen.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

EBV-associated post-transplant lymphoproliferative disorder after umbilical cord blood transplantation in adults with hematological diseases

Sanz

Arango

Senent

et al. 2013

Bone Marrow Transplant

View full text Add to dashboard Cite

We analyzed the incidence, clinicopathological features, risk factors and prognosis of patients with EBV-associated post-transplant lymphoproliferative disorder (EBV-PTLD) in 288 adults undergoing umbilical cord blood transplantation (UCBT) at a single institution. Twelve patients developed proven EBV-PTLD at a median time of 73 days (range, 36-812). Three-year cumulative incidence (CI) of EBV-PTLD was 4.3% (95% CI: 1.9-6.7). All patients presented with extranodal involvement. Most frequently affected sites were the liver, spleen, central nervous system (CNS), Waldeyer's ring and BM in 7, 6, 4, 3 and 3 patients, respectively. One patient had polymorphic and 11 had monomorphic EBV-PTLD (7 diffuse large B-cell lymphomas not otherwise specified, 4 plasmablastic lymphomas). We confirmed donor origin and EBV infection in all histological samples. EBV-PTLD was the cause of death in 11 patients at a median time of 23 days (range, 1-84). The 3-year CI of EBV-PTLD was 12.9% (95% CI: 3.2-22.5) and 2.6% (95% CI: 0.5-4.7) for patients receiving reduced-intensity conditioning (RIC) and myeloablative conditioning, respectively (Po0.0001). In conclusion, adults with EBV-PTLD after UCBT showed frequent visceral and CNS involvement. The prognosis was poor despite routine viral monitoring and early intervention. An increased risk of EBV-PTLD was noted among recipients of RIC regimens.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

EBV-associated post-transplant lymphoproliferative disorder after umbilical cord blood transplantation in adults with hematological diseases

Sanz

Arango

Senent

et al. 2013

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…Delecluse et al reported 16 cases in the oral cavity oh HIV patients in 1997 [3], originally this first cases have been considered as variant of diffuse large B-cell lymphoma (DLBCL) [3]. PBL is strongly associated with HIV infection, but occurs also in other immunosuppressive situations such as from solid organ and bone marrow transplantation, lymphoproliferative or autoimmune disorders [10,11]. The occurrence of PBL in extra-oral sites have been described [9].…”

Section: Discussionmentioning

confidence: 99%

Plasmablastoid Lymphoma in Patients with Human Immunodeficiency Virus: A Diagnosis Challenge

Jelloul¹,

Sattar²,

Wind³

et al. 2017

J Emerg Infect Dis

View full text Add to dashboard Cite

In this era of Highly Active Antiretroviral Therapy (HAART), we see that incidence of neoplasic diseases among patients affected by Human Immonudeficiency Virus (HIV) is increasing. Plasmablastic lymphoma (PBL) is an example of neoplastic condition specific to HIV patients. It is a subtype of diffuse large B-cell lymphoma (DLBCL) recently described in the 2008 WHO classification of lymphoproliferative disorder. PBL is characterized by its aggressive nature and plasmacytic differentiation and usually occurs in the oral cavity or jaw of HIV-infected individuals. However, several cases of PBL involving extraoral sites have been reported in immunocompetent individuals. This entity is a diagnostic challenge and need integration of clinical, pathological, genetic and microbiologic features. Several types of lymphoma present with plasmablastoid differenciation and may give rise to some difficulties for a differential diagnosis. We give some anatomopathological, molecular and genetic details for each subtype and we will illustrate the difficulty for the diagnosis with two cases. The first case is a patient with plasmablastic lymphoma that present with unusual negative immunoreactivity for CD 138 (10% of PBL cases). The second case has clinical, epidemiological and pathological characteristic of plasmablastic lymphoma but HHV8 positivity is a criteria for considering extra-cavitary PEL as the most relevant diagnosis.

show abstract

“…(9) A recent single-centre study of nine HIV-negative PBL patients who received chemotherapy (CHOP or hyperCVAD) reported that seven patients achieved CR and one patient achieved partial remission. (10) In addition, four of these patients underwent autologous peripheral blood haematopoietic stem cell transplantation during the first CR. Seven patients were alive at the follow-up (median = 23.9 months).…”

Section: A S E R E P O R Tmentioning

confidence: 99%

“…Seven patients were alive at the follow-up (median = 23.9 months). (10) Although only a small number of PBL cases have been examined, PBL seems to have a high degree of malignancy and associated with a poor prognosis relative to NHLs.…”

Section: A S E R E P O R Tmentioning

confidence: 99%

Treatment of plasmablastic lymphoma with multiple organ involvement

Liang

Wang²,

Chen³

et al. 2014

smedj

View full text Add to dashboard Cite

Human immunodeficiency virus (HIV)-negative plasmablastic lymphoma: A single institutional experience and literature review

Cited by 105 publications

References 35 publications

EBV-associated post-transplant lymphoproliferative disorder after umbilical cord blood transplantation in adults with hematological diseases

EBV-associated post-transplant lymphoproliferative disorder after umbilical cord blood transplantation in adults with hematological diseases

Plasmablastoid Lymphoma in Patients with Human Immunodeficiency Virus: A Diagnosis Challenge

Treatment of plasmablastic lymphoma with multiple organ involvement

Contact Info

Product

Resources

About